Leerink Partnrs Forecasts AstraZeneca Q2 Earnings

AstraZeneca PLC (NASDAQ:AZN) – Analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for AstraZeneca in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will post earnings per share of $1.09 for the quarter. The consensus estimate for AstraZeneca’s current full-year earnings is $4.13 per share. Leerink Partnrs also issued estimates for AstraZeneca’s Q3 2025 earnings at $1.11 EPS.

A number of other analysts have also recently weighed in on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Up 2.0 %

AZN stock opened at $72.36 on Friday. The firm has a 50-day moving average price of $67.27 and a 200-day moving average price of $73.70. AstraZeneca has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $224.39 billion, a P/E ratio of 34.62, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%.

Institutional Investors Weigh In On AstraZeneca

A number of institutional investors have recently modified their holdings of the company. Callan Family Office LLC acquired a new stake in AstraZeneca during the 4th quarter worth about $1,505,000. Hartford Funds Management Co LLC increased its holdings in AstraZeneca by 5.6% in the fourth quarter. Hartford Funds Management Co LLC now owns 11,238 shares of the company’s stock worth $736,000 after purchasing an additional 598 shares in the last quarter. E Fund Management Co. Ltd. boosted its holdings in shares of AstraZeneca by 27.4% during the 4th quarter. E Fund Management Co. Ltd. now owns 6,920 shares of the company’s stock worth $453,000 after buying an additional 1,488 shares in the last quarter. Chung Wu Investment Group LLC bought a new stake in shares of AstraZeneca in the 4th quarter valued at $482,000. Finally, Vestmark Advisory Solutions Inc. boosted its stake in AstraZeneca by 25.6% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 30,582 shares of the company’s stock worth $2,004,000 after acquiring an additional 6,229 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.